Op-Ed: FTC Adds Fuel to the Fire for PBMs. Will Congress Deliver Real Reform?

The FTC's reports and legal actions target PBMs for inflating drug costs and restricting access, focusing on insulin and specialty generics.

Previous
Previous

Lawmakers want Indiana to own its own pharmacy benefit manager for state plans like Medicaid

Next
Next

Kansas pharmacists are closing their doors as they seek a way to save their businesses struggling from PBM practices